Please assess the completion status of the following clinical trial:

Trial Title: Open-trial on the Prevention of Chronic Migraines With the CEFALY Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of chronic migraine meeting the diagnostic criteria listed in ICHD-III beta (2013) section 1, migraine (1), with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, migraine with brainstem aura, ophthalmoplegic migraine-recurrent painful ophthalmoplegic neuropathy, migrainous infarction) will be enrolled. They are required during baseline to have ≥15 headache days with each day consisting of ≥4 hours of continuous headache and with ≥50% of days being migraine or probable migraine days; and ≥4 distinct headache episodes, each lasting ≥4 hours.~Both patients with or without acute medication overuse (medication overuse headache - MOH) will be recruited~Exclusion Criteria:~1. Women: Pregnant, lactating or \<6 months post partum~2. For patients already on treatment with medications in the following classes: antihypertensives, antidepressants, antiepileptics, no dose change of those medications is allowed for at least 3 months before start of baseline and during the entire study period.~3. For patients treated with Botox, no injection within 4 months before start of baseline or during the study.~4. Diagnosis of other primary or secondary headache disorders, except of Medication Overuse Headache~5. A Beck Depression Inventory score of \>24 at baseline~6. Psychiatric disorders that could have interfered with study participation~7. Intolerance to supraorbital neurostimulation that makes the treatment not applicable (test of nociceptive threshold with specific Cefaly program)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Daily trigeminal nerve stimulation session of 20 minutes with CEFALY

Based on this trial design, predict the completion outcome and termination type (if applicable).